BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 27626178)

  • 1. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China.
    Xu H; Lin A; Shao X; Shi W; Zhang Y; Yan W
    Oncotarget; 2016 Dec; 7(50):83775-83783. PubMed ID: 27626178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Punch biopsy guided by both colposcopy and HR-HPV status is more efficient for identification of immediate high-grade squamous intraepithelial lesion or worse among HPV-infected women with atypical squamous cells of undetermined significance.
    Ding Z; Li Y; Chen A; Song M; Zhang Y
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():32-36. PubMed ID: 27816739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
    Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
    J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.
    Iwata T; Hasegawa T; Ochiai K; Takizawa K; Umezawa S; Kuramoto H; Ohmura M; Kubushiro K; Arai H; Sakamoto M; Motoyama T; Watanabe K; Aoki D
    Reprod Sci; 2015 Dec; 22(12):1509-15. PubMed ID: 26092278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study.
    Nakamura Y; Matsumoto K; Satoh T; Nishide K; Nozue A; Shimabukuro K; Endo S; Nagai K; Oki A; Ochi H; Morishita Y; Noguchi M; Yoshikawa H
    Int J Clin Oncol; 2015 Oct; 20(5):974-81. PubMed ID: 25652908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions of the uterine cervix with human papilloma virus infection among young women aged less than 25 years.
    Ryu KJ; Lee S; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
    Diagn Cytopathol; 2016 Dec; 44(12):959-963. PubMed ID: 27714942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV-ISH-Negative Invasive Cervical Squamous Cell Carcinoma: Histologic and Pap Test Results.
    Alexander C; White M; Maleki Z; Rodriguez EF
    Acta Cytol; 2019; 63(5):417-423. PubMed ID: 31195388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
    Castle PE; Reid J; Dockter J; Getman D
    J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
    Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
    Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.
    Dijkstra MG; van Niekerk D; Rijkaart DC; van Kemenade FJ; Heideman DA; Snijders PJ; Meijer CJ; Berkhof J
    Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):55-63. PubMed ID: 23733907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Papillomavirus Genotyping to Predict the Risk of Cervical Precancerous Lesions or Cancer in Women with Minor Abnormal Cytology in China.
    Lin CQ; Cui JF; Zhang X; Pan QJ; Chen W; Qiao YL
    Acta Cytol; 2015; 59(5):405-11. PubMed ID: 26565687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification for cervical neoplasia using extended high-risk HPV genotyping in women with ASC-US cytology: A large retrospective study from China.
    Tao X; Austin RM; Yu T; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
    Cancer Cytopathol; 2022 Apr; 130(4):248-258. PubMed ID: 34874615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea.
    Jung S; Lee B; Lee KN; Kim Y; Oh EJ
    Arch Pathol Lab Med; 2016 Mar; 140(3):276-80. PubMed ID: 26927723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of High-Risk Human Papillomavirus Testing for Atypical Glandular Cells on Cervical Cytology.
    Komatsu H; Oishi T; Osaku D; Sawada M; Kudoh A; Nonaka M; Chikumi J; Sato S; Harada T
    Acta Cytol; 2018; 62(5-6):405-410. PubMed ID: 29990964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the clinical significance of human papillomavirus (HPV) 53.
    Padalko E; Ali-Risasi C; Van Renterghem L; Bamelis M; De Mey A; Sturtewagen Y; Vastenavond H; Vanden Broeck D; Weyers S; Praet M
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():7-9. PubMed ID: 26026728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
    Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
    Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L; Oštrbenk A; Poljak M; Arbyn M
    J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.